New Syndicated Report: Cancer Monitoring US Landscape - ctDNA MRD Uptake

Are ctDNA monitoring tests being used in clinical practice? Which ctDNA monitoring tests are oncologists currently using, and why? What are their unmet needs and expectations from a new test?

Purdie Pascoe is delighted to announce the findings from the first wave of our syndicated ctDNA Cancer Monitoring study have been published.

The methodology consists of 20-minute quantitative online interviews with 150 Medical and Hemato-Oncologists in the US. The research explores current and anticipated usage of ctDNA monitoring across different cancer stages, revealing the preferences and needs of Oncologists. Further insights are revealed around behaviours and perceptions surrounding this new trending indication.

Wave 1: Report (including interactive dashboard link) is available to purchase
Wave 2: Scheduled for October 2024

If you are interested in accessing the wave 1 data or signing up for wave 2, please use the button below to contact Marianne Fillion, Purdie Pascoe’s Precision Medicine and In Vitro Diagnostics Lead, and she will be delighted to provide you with more details about the study.